These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31345339)

  • 1. Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.
    Nakasuka T; Ichihara E; Makimoto G; Maeda Y; Kiura K
    J Thorac Oncol; 2019 Aug; 14(8):e168-e169. PubMed ID: 31345339
    [No Abstract]   [Full Text] [Related]  

  • 2. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P; Zhang J; Shang C; Zhang L
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
    Sehgal K; Peters MLB; VanderLaan PA; Rangachari D; Kobayashi SS; Costa DB
    J Thorac Oncol; 2019 Jan; 14(1):e1-e3. PubMed ID: 29981924
    [No Abstract]   [Full Text] [Related]  

  • 4. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
    J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.
    Suzuki S; Haratani K; Takahama T; Watanabe S; Takegawa N; Hayashi H; Takeda M; Yonesaka K; Nakagawa K
    J Thorac Oncol; 2019 Mar; 14(3):e50-e52. PubMed ID: 30782383
    [No Abstract]   [Full Text] [Related]  

  • 6. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
    Tsuji T; Ozasa H; Aoki W; Aburaya S; Funazo T; Furugaki K; Yoshimura Y; Ajimizu H; Okutani R; Yasuda Y; Nomizo T; Uemasu K; Hasegawa K; Yoshida H; Yagi Y; Nagai H; Sakamori Y; Ueda M; Hirai T; Kim YH
    Mol Cancer Res; 2019 Jan; 17(1):212-224. PubMed ID: 30171175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
    Takegawa N; Hayashi H; Iizuka N; Takahama T; Ueda H; Tanaka K; Takeda M; Nakagawa K
    Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
    [No Abstract]   [Full Text] [Related]  

  • 8. Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    Nakanishi Y; Masuda S; Iida Y; Takahashi N; Hashimoto S
    J Thorac Oncol; 2017 Dec; 12(12):e202-e204. PubMed ID: 29169525
    [No Abstract]   [Full Text] [Related]  

  • 9. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
    Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V; Ou SH
    Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
    Srinivasamaharaj S; Salame BK; Rios-Perez J; Kloecker G; Perez CA
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1227-1233. PubMed ID: 27744726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K; Naruse I; Shimizu K; Asao T
    J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib.
    Song L; Zeng L; Zhang Y
    Thorac Cancer; 2022 Apr; 13(7):1095-1097. PubMed ID: 35150066
    [No Abstract]   [Full Text] [Related]  

  • 16. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
    Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M; Altavilla G; Rosell R
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
    Paik J; Dhillon S
    Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.